Lite Strategy Reports FY2026 Q1 Results, Launches $100M Litecoin Treasury Strategy

San Diego, United States, November 17th, 2025, Chainwire – Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”) today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company’s digital asset treasury strategy as well as its pharmaceutical operations.

“Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus,” Board Member Charlie Lee said. 

“We recently celebrated Litecoin’s 14th anniversary and its unblemished track record of reliability and uptime. LITS provides investors the only US publicly traded company to gain institutional exposure to Litecoin, both for portfolio diversification and long-term value.”

“Fiscal year 2026 will showcase the results of the transformative steps taken by Lite Strategy. Since the start of our strategic alternatives process in fiscal year 2025, we have prioritized maximizing the value of our assets for stockholders.

Starting with the successful sale of our clinical asset, ME-344 (now known as WE-868), currently being developed for adults with obesity at Aardvark Therapeutics, and continuing through the close of our $100 million PIPE offering in July 2025 that kicked off our Litecoin digital asset treasury strategy in the first quarter of this fiscal year,” said Jay File, CEO, CFO.

First Quarter Fiscal Year 2026 and Recent Highlights

• Raised $100 million in aggregate gross proceeds, commencing the Company’s long-term strategic plan with Litecoin as a digital asset treasury reserve asset.
• Officially became the first U.S.-listed public company to adopt Litecoin as a primary reserve asset with the acquisition of 929,548 Litecoin (LTC) tokens, implementing a new strategy built on a digital asset infrastructure and long-term capital innovation.
• Entered into a strategic partnership with GSR, a leading crypto investment firm, to guide LITS’ digital asset treasury strategy, ensuring robust governance, execution, and market expertise.
• Brought on world-class board members, Charlie Lee, creator of Litecoin, and Joshua Riezman, U.S. Chief Strategy Officer at GSR.
• Rebranded from MEI Pharma to Lite Strategy, including changing the Company’s corporate name and NASDAQ Stock Market ticker from MEIP to LITS, and unveiling a new corporate logo and website. The rebranding underscores the Company’s commitment to building a long-term corporate strategy around LTC as its primary reserve asset.
• Announced a $25 million share repurchase program, advancing LITS from the initial phase of Litecoin accumulation to active capital market operations and allowing LITS to leverage our nearly 1 million LTC treasury in October, which became a key difference from passive investment structures like exchange-traded funds.

“As we progress further into fiscal year 2026, we continue to evaluate our clinical assets, including the commencement of pre-clinical studies with voruciclib in non-oncology disease indications for potential licensing to third parties, and pursuing licensing or sale opportunities with zandelisib,” said Jay File. 

“We will consider opportunities to deploy our recently announced $25 million stock buyback program until our discount to NAV is normalized. We look forward to executing on all our corporate objectives as we progress through fiscal year 2026.”

As of September 30, 2025, the Company had $12.21 million in working capital with no outstanding debt.

To learn more about Lite Strategy, visit the Company’s homepage at https://litestrategy.com.

To learn more about Litecoin and its role in Lite Strategy’s treasury, visit the About Litecoin page at https://litestrategy.com/about-litecoin/.

To learn more about the transaction with Aardvark, read the Form 8-K filing at https://investor.meipharma.com/sec-filings/sec-filing/8-k/0000950170-24-117406.

For current holdings and related Company metrics, visit Lite Strategy’s dashboard at https://litestrategy.com/dashboard/.

About Lite Strategy, Inc. (LITS)

Lite Strategy, Inc. (NASDAQ: LITS) is the first U.S. publicly traded company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug candidates to focus on pioneering institutional-grade digital asset treasury strategies, in partnership with leading innovators across blockchain, finance, and technology.

Forward-Looking Statements

Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding our future actions, prospective products and activities, future performance or results. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, risk relating to being able to repurchase our shares in the market on attractive terms or at all, maintaining our current listing on Nasdaq, our ability to retain and attract senior management and other key employees, fluctuations in the market price of LTC and any associated impairment charges that we may incur as a result of a decrease in the market price of LTC below the value at which LTC is carried on our balance sheet, changes in the accounting treatment relating to our LTC holdings, our ability to achieve profitable operations, government regulation of cryptocurrencies and online betting, changes in securities laws or regulations, customer acceptance of new products and services including our LTC treasury strategy, our ability to utilize our repurchase program, the demand for our products and our customers’ economic condition, the impact of competitive products and pricing, our proprietary rights, general economic conditions and other risk factors detailed in our annual report and other filings with the SEC. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact

CEO, CFO

Justin J. File

Lite Strategy, Inc.

investor@litestrategy.com

858-369-7199